Selectivity profile of the poly(ADP-ribose) polymerase (PARP) inhibitor, A-966492
bioRxiv (Cold Spring Harbor Laboratory)2017
Citations Over Time
Abstract
Abstract Among the clinical inhibitors of poly(ADP-ribose) polymerases (PARPs) and the commonly used PARP research tool compounds, veliparib and niraparib were recently identified as the most selective inhibitors of PARP1 and PARP2. We characterized the potency of A-966492, a PARP inhibitor with a chemical structure similar to veliparib and niraparib, in in vitro inhibition experiments of six PARP family enzymes. We find that the selectivity of A-966492 for PARP1 and PARP2 is intermediate between veliparib and niraparib.
Related Papers
- → An Overview of PARP Inhibitors for the Treatment of Breast Cancer(2021)376 cited
- → The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma(2018)96 cited
- → Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor(2021)28 cited
- → Abstract 2965: Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model(2014)1 cited
- → Abstract 3421: Differential potentiation of temozolomide and camptothecin by the PARP inhibitors olaparib and veliparib in relationship with their PARP-DNA trapping abilities, and lack of impact of PARP inhibitors on cisplatin activity.(2013)